Document Detail


Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA.
MedLine Citation:
PMID:  23151649     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The Bowel Function Questionnaire (BFQ) has been used in clinical trials to assess symptoms during and after pelvic radiotherapy (RT). This study evaluated the importance of symptoms in the BFQ from a patient perspective.
METHODS: Patients reported presence or absence of symptoms and rated importance of symptoms at baseline, 4 weeks after completion of pelvic RT, and 12 and 24 months after RT. The BFQ measured overall quality of life (QOL) and symptoms of nocturnal bowel movements, incontinence, clustering, need for protective clothing, inability to differentiate stool from gas, liquid bowel movements, urgency, cramping, and bleeding. Bowel movement frequency also was recorded. A content validity questionnaire (CVQ) was used to rate symptoms as "not very important," "moderately unimportant," "neutral," "moderately important," or "very important."
RESULTS: Most of the 125 participating patients rated all symptoms as moderately or very important. Generally, patients gave similar ratings for symptom importance at all study points, and ratings were independent of whether the patient experienced the symptom. Measures of greatest importance (moderately or very important) at baseline were ability to control bowel movements (94 %), not having to wear protective clothing (90 %), and not having rectal bleeding (94 %). With the exception of need for protective clothing, the presence of a symptom at 4 weeks was associated with significantly worse QOL (P < .01 for all).
CONCLUSIONS: The BFQ has excellent content validity. Patients rated most symptoms as moderately or very important, indicating the BFQ is an appropriate tool for symptom assessment during and after pelvic RT.
Authors:
Pamela J Atherton; Michele Y Halyard; Jeff A Sloan; Robert C Miller; Richard L Deming; T H Patricia Tai; Kathy J Stien; James A Martenson
Related Documents :
24175169 - Assessment scales for delirium: a review.
10403149 - The relationship of dysfunctional attitudes to personality in depressed patients.
23581869 - Culturally sensitive and universal measure of resilience for japanese populations: tach...
12755659 - Chronic depression and comorbid personality disorders: response to sertraline versus im...
20046389 - Comparison of clinical features and personality dimensions between patients with major ...
23299259 - Psychometric study of the neurobehavioral symptom inventory.
8074599 - Patient-carried card prompts vs computer-generated prompts to remind private practice p...
12150399 - A meta-analytic review of treatment of homosexuality.
20554429 - Are randomized trials conducted in china or india biased? a comparative empirical analy...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-11-15
Journal Detail:
Title:  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer     Volume:  21     ISSN:  1433-7339     ISO Abbreviation:  Support Care Cancer     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-02-28     Completed Date:  2013-09-17     Revised Date:  2014-05-14    
Medline Journal Info:
Nlm Unique ID:  9302957     Medline TA:  Support Care Cancer     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1193-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Diagnostic Self Evaluation
Diarrhea / prevention & control*,  psychology
Female
Gastrointestinal Agents / therapeutic use*
Humans
Intestines / physiopathology,  radiation effects*
Male
Middle Aged
Octreotide / therapeutic use*
Pelvic Neoplasms / psychology,  radiotherapy*
Pelvis
Quality of Life
Questionnaires
United States
Grant Support
ID/Acronym/Agency:
CA-25224/CA/NCI NIH HHS; CA-35101/CA/NCI NIH HHS; CA-35103/CA/NCI NIH HHS; CA-35119/CA/NCI NIH HHS; CA-35195/CA/NCI NIH HHS; CA-35267/CA/NCI NIH HHS; CA-35269/CA/NCI NIH HHS; CA-35415/CA/NCI NIH HHS; CA-35431/CA/NCI NIH HHS; CA-37417/CA/NCI NIH HHS; CA-52654/CA/NCI NIH HHS; CA-60276/CA/NCI NIH HHS; CA-63849/CA/NCI NIH HHS; U10 CA037404/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Gastrointestinal Agents; RWM8CCW8GP/Octreotide
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report.
Next Document:  Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma tre...